Kolon TissueGene’s phase 3 trial found its osteoarthritis therapy did not improve knee pain or function versus placebo, leaving the biotech to await results from a second late-stage study before deciding the...
And it begins... the Korean biotech company whose product, Cartistem, has been approved in Korea since 2012, passed Phase 3 in Japan, and is now entering the West.
Sad day for the industry, here's a summary of the CEO/Executive Chairman's readouts of the trials.
This marks the first stem cell therapy for KOA to reach Phase III in China. The race is heating up...
The Living Knee project is hoping to replace traditional knee replacements, expected to begin Phase 1 trials around 2028.
Building on work at the University of Wisconsin-Madison, the Australian biotech company expects to release data from its Phase 3 iPSC-derived MSC KOA & Phase 2 Graft-vs-Host-Disease trials in the coming months.
The company is working on iPSC-derived, AAV, and small molecule therapies for neurodegenerative, orthopedic, and blood-based disorders, with the help of OpenAI's models which seem to be accelerating life science research.
The 4 US and 1 European patents cover the design and manufacturing of the company's placental therapies. The company is targeting various applications across orthopedics, urology, and wound care.
The Korean biotech company published the multicenter Phase 1 results in Nature, with 24-week follow-up MRI data that look promising as they continue development.
The companies are working to bring jellyfish-derived Collagen Type Zero to North America, aiming to advance wound care and regenerative medicine with a sustainable alternative to mammalian collagen.
